Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025)

Dianthus Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $5000.0 for Q3 2025.

• In Q3 2025, Capital Expenditures fell 80.0% year-over-year to $5000.0; the TTM figure through Sep 2025 stood at $106000.0 (up 26.19% YoY), while the FY2024 annual figure was $105000.0, down 4.55% from the prior year.
• Capital Expenditures was $5000.0 for Q3 2025 at Dianthus Therapeutics, down from $46000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q3 2021 to a low of -$1.2 million in Q4 2021.
• Historically, Capital Expenditures has averaged $22578.9 across 5 years, with a median of $25000.0 in 2024.
• Biggest YoY gain for Capital Expenditures was 5555.0% in 2021; the steepest drop was 686.38% in 2021.
• A 5-year view of Capital Expenditures shows it stood at -$1.2 million in 2021, then surged by 102.32% to $29000.0 in 2022, then plunged by 65.52% to $10000.0 in 2023, then jumped by 210.0% to $31000.0 in 2024, then tumbled by 83.87% to $5000.0 in 2025.
• The last three Capital Expenditures figures came in at $5000.0 (Q3 2025), $46000.0 (Q2 2025), and $24000.0 (Q1 2025), per Business Quant data.